Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01454063 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification
A Phase 3 study, sponsored by Omeros Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 405
- Enrollment target
NCT01454063 is a Phase 3 study that has completed, run by Omeros Corporation. The registered enrollment target is 405 participants.
The verdict
NCT01454063, a Phase 3 study, has completed, sponsored by Omeros Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 405 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and efficacy of OMS302 (the study drug) for maintaining intraoperative mydriasis in individuals undergoing Intraocular Lens Replacement (ILR) surgery.
Interventions
- DRUG Placebo
- DRUG OMS302
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 405 participants |
| Start Date | 2011-09 |
| Est. Completion | 2012-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01454063
The ClinicalTrials.gov registry entry for NCT01454063 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 405 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Omeros Corporation, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01454063 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01454063 about?
NCT01454063 is a clinical study titled "Safety and Efficacy of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification". The purpose of this study is to determine the safety and efficacy of OMS302 (the study drug) for maintaining intraoperative mydriasis in individuals undergoing Intraocular Lens Replacement (ILR) surgery.
What is the current status of trial NCT01454063?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 405 participants. The study started on 2011-09. Estimated completion is 2012-03.
What interventions are being tested in trial NCT01454063?
The interventions under investigation include: Placebo (DRUG), OMS302 (DRUG).
Who is sponsoring clinical trial NCT01454063?
This trial is sponsored by Omeros Corporation, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.